NDA 020834 · Kenvue Brands
Rogaine Extra Strength (For Men)
Minoxidil · Topical · Arteriolar Vasodilator
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Nov 14, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
93
21 Phase 3, 12 recruiting
FAERS reports
33,735
4,726 serious, 453 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 9, 2026.
Use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 14, 1997 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- ROGAINE EXTRA STRENGTH (FOR MEN) · MINOXIDIL 5% · SOLUTION, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Minoxidil" as an intervention, any sponsor and status, largest first.
- HALT Progression of Polycystic Kidney Disease Study APivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00283686 · 558 participants · Start Jan 2006 · Primary completion Jun 2014
Drug: Lisinopril; Telmisartan and 1 more · For: Kidney, Polycystic
Sites: Aurora, Colorado; Atlanta, Georgia; Kansas City, Kansas · 7 sites in all
- Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic AlopeciaPivotal-lookingActive, not recruiting
Industrial Farmacéutica Cantabria, S.A.Industry
NCT05888922 · 520 participants (planned) · Start Oct 17, 2024 · Primary completion Oct 2026
Drug: Minoxidil Tablets; Minoxidil Topical and 2 more · For: Androgenetic Alopecia; Female Pattern Baldness
Sites: Bad Bentheim, Germany; Berlin, Germany; Bochum, Germany · 27 sites in all
- Androgenic Alopecia TH07 Clinical TrialPivotal-lookingRecruiting
Triple Hair IncIndustry
NCT07435012 · 420 participants (planned) · Start Apr 2026 · Primary completion Dec 2027
Drug: TH07; TH07 and 1 more · For: Androgenic Alopecia
Sites: Vancouver, Canada
- Clinical Trial in Females for Female Pattern Hair LossPivotal-lookingCompleted
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT01226459 · 404 participants · Start Sep 2010 · Primary completion Aug 2011
Drug: 5% Minoxidil Topical Foam; Vehicle Topical Foam · For: Androgenetic Alopecia
Sites: Los Angeles, California; San Diego, California; Wichita, Kansas · 17 sites in all
- Topical Application of Lactobacillus Reuteri for Androgenetic AlopeciaPivotal-lookingRecruiting
Shenzhen People's HospitalAcademic, hospital or other
NCT07370519 · 388 participants (planned) · Start Jan 25, 2026 · Primary completion Jan 2027
Drug: Lactobacillus reuteri; Inactivated Lactobacillus reuteri and 2 more · For: Androgenetic Alopecia (AGA)
Sites: Shenzhen, China
- Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.Pivotal-lookingNot yet recruiting
Eurofarma Laboratorios S.A.Industry
NCT07529977 · 372 participants (planned) · Start Jan 31, 2027 · Primary completion Oct 30, 2028
Drug: Minoxidil oral solution; Placebo oral solution · For: Androgenetic Alopecia; Androgenetic Alopecia (AGA)
Sites: Itapevi, Brazil
- A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair LossPivotal-lookingCompleted
Johnson & Johnson Consumer and Personal Products WorldwideJohnson & Johnson (Janssen) (JNJ)
NCT00151515 · 352 participants · Start Oct 2003 · Primary completion Jul 2004
Drug: minoxidil · For: Androgenetic Alopecia
Sites: La Jolla, California; San Francisco, California; Vallejo, California · 15 sites in all
- Treatment of Androgenetic Alopecia in Men for 24 WeeksPivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04721548 · 336 participants · Start Mar 2, 2023 · Primary completion Mar 6, 2024
Drug: Minoxidil Topical Foam; Placebo · For: Alopecia
Sites: São Paulo, Brazil
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- adverse drug reaction8,609
- drug ineffective6,323
- application site pruritus2,582
- off label use1,521
- application site irritation1,251
- headache1,112
- application site pain1,110
- alopecia986
- inappropriate schedule of product administration826
- application site dryness747
- condition aggravated736
- product administered at inappropriate site705
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 95 |
| 2005 | 122 |
| 2006 | 128 |
| 2007 | 89 |
| 2008 | 113 |
| 2009 | 130 |
| 2010 | 149 |
| 2011 | 167 |
| 2012 | 219 |
| 2013 | 152 |
| 2014 | 196 |
| 2015 | 589 |
| 2016 | 829 |
| 2017 | 796 |
| 2018 | 1,115 |
| 2019 | 1,176 |
| 2020 | 2,457 |
| 2021 | 4,839 |
| 2022 | 7,986 |
| 2023 | 5,654 |
| 2024 | 3,111 |
| 2025 | 2,226 |
| 2026 | 1,397 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.
Penha MA, Miot HA, Kasprzak M, et al. · JAMA Dermatol 2024 · Randomized Controlled Trial, Comparative Study
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, et al. · J Am Acad Dermatol 2022 · Systematic Review, Research Support, N.I.H., Extramural
- The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Adil A, Godwin M · J Am Acad Dermatol 2017 · Meta-Analysis, Systematic Review
- Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.
Fields JR, Vonu PM, Monir RL, et al. · Dermatol Ther 2020 · Systematic Review
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.